Graft-derived cell-free DNA as a marker of transplant graft injury

Therapeutic Drug Monitoring

Volumn 38, Issue 2, 2016, Pages S75-S79

  Oellerich, Michael ^a   Walson, Philip D ^a   Beck, Julia ^b   Schmitz, Jessica ^a   Kollmar, Otto ^a   Schütz, Ekkehard ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Chronix Biomedical GmbH   (Germany)

Author keywords

Cell free DNA; Liquid biopsy; Transplant graft injury

Indexed keywords

CELL DNA; GRAFT DERIVED CIRCULATING CELL FREE DNA; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA;

ACUTE GRAFT REJECTION; CELL FREE SYSTEM; CLINICAL OUTCOME; DRUG MONITORING; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VALIDATION STUDY; BLOOD; GENETICS; GRAFT SURVIVAL;

BIOMARKERS; DNA; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84944338690     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000239     Document Type: Review

References (29)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR. 2010; Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
2. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Eng J Med. 2002;346:580-590.
3. Land WG. Chronic allograft dysfunction: a model disorder of innate immunity. Biomed J. 2013;36:209-228.
4. Schröppel B, Heeger PS. Gazing into a crystal ball to predict kidney transplant outcome. J Clin Invest. 2010;120:1803-1806.
5. Yazigi NA. Long term outcomes after pediatric liver transplantation. Pediatr Gastroenterol Hepatol Nutr. 2013;16:207-218.
6. Gallo A, Esquivel CO. Current options for management of biliary atresia. Pediatr Transplant. 2013;17:95-98.
7. Lund LH, Edwards LB, Kucheryavaya AY, et al; International Society for Heart and Lung Transplantation. The registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant Report-2013; focus theme: age. J Heart Lung Transplant. 2013;32:951-964.
8. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120:1848-1861.
9. Wieland E, Olbricht CJ, Süsal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010;32:560-572.
10. Crettol S, Venetz JP, Fontana M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307-315.
11. Falck P, Asberg A, Guldseth H, et al. Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant patients. Transplantation. 2008;85:179-184.
12. Rianthavorn P, Ettenger RB, Malekzadeh M, et al. Noncompliance with immunosuppressive medications in pediatric and adolescent patients receiving solid-organ transplants. Transplantation. 2004;77:778-782.
13. American Society of Nephrology. American society of Nephrology renal research report. J Am Soc Nephrol. 2005;16:1886-1903.
14. Meeusen JW, Lieske JC. Looking for a better creatinine. Clin Chem. 2014;60:1036-1039.
15. Rodriguez-Perálvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12:2797-2814.
16. Rodriguez-Perálvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2013;58: 262-270.
17. Miller CA, Fildes JE, Ray SG, et al. Non-invasive approaches for the diagnosis of acute cardiac allograft rejection. Heart. 2013;99:445-453.
18. Su VC, Harrison J, Rogers C, et al. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46:57-67.
19. De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014;6:241ra77.
20. Lo YM, Tein MS, Pang CC, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998;351: 1329-1330.
21. Sigdel TK, Vitalone MJ, Tran TQ, et al. A rapid noninvasive assay for the detection of renal transplant injury. Transplantation. 2013;96:97-101.
22. Snyder TM, Khush KK, Valantine HA, et al. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A. 2011;108:6229-6234.
23. Beck J, Bierau S, Balzer S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013;59:1732-1741.
24. Oellerich M, Kanzow P, Beck J, et al. Graft-derived cell-free DNA (GcfDNA) as a sensitive measure of individual graft integrity after liver transplantation. Am J Transplant. 2014;14(suppl 1):874.
25. Oellerich M, Schütz E, Kanzow P, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit. 2014; 36:136-140.
26. Londoño MC, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant. 2012;12:1370-1377.
27. Kanzow P, Kollmar O, Schütz E, et al. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation. 2014;98:e43-45.
28. Yu SCY, Lee SWY, Jiang P, et al. High-Resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem. 2013;59:1228-1237.
29. Beck J, Schmitz J, Kanzow P, et al. Absolute quantification of graft derived cell-free DNA (GcfDNA) early after liver transplantation (LTx) using droplet digital PCR. Clin Chem. 2014;60(suppl 1):S194-S195.